Optimizerx Earnings Call: Profits Strong, Growth Cautious

Optimizerx Corporation ((OPRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Optimizerx Corporation’s latest earnings call struck a cautiously upbeat tone as management highlighted robust 2025 profitability, strong cash generation, and solid recurring-revenue metrics, even as they warned of softer near-term demand. Executives emphasized that cash flow, margins, and net revenue retention remain bright spots, offsetting pressure from shifting client behavior and non-recurring revenue tailwinds.

Revenue Growth and Rule of 40 Profitability

Optimizerx delivered Q4 revenue of $32.2 million and full-year 2025 revenue of $109.4 million, demonstrating steady top-line execution. Adjusted EBITDA reached $12.0 million in Q4 and $24.3 million for the year, translating into margins above 20% and achieving coveted Rule of 40 performance.

Cash Generation and Balance Sheet Strengthening

Operating cash flow surged to $18.7 million in 2025 from $4.9 million a year earlier, pushing free cash flow to nearly $19 million. Cash and short-term investments climbed to $23.4 million while the company paid down $8 million of debt, including $6 million ahead of schedule.

Profitability and Earnings Outperformance

Non-GAAP net income in Q4 jumped to $9.9 million, or $0.51 per share, versus $5.5 million, or $0.30 per share, a year ago, while GAAP net income swung to a $5.0 million profit from a small loss. Management underscored that both adjusted EBITDA and free cash flow more than doubled year over year, highlighting meaningful operating leverage.

Gross Margin Expansion Driven by Mix

Fourth-quarter gross margin expanded sharply to 74.8% from 68.1% in the prior-year quarter, helped by a favorable solution and channel mix. Higher-margin specialty messaging was a key contributor, giving the quarter an unusually rich margin profile that boosted overall profitability.

Retention and Productivity Underpin Operations

Net revenue retention remained strong at 116%, signaling that existing customers are continuing to spend and expand. Revenue per full-time employee rose to $839,000 from $701,000, a roughly 20% increase that points to improved productivity and scalable operations.

Commercial Momentum and DAAP Adoption

The company reported expanding multi-brand enterprise deals, particularly in oncology and medical technology, where clients are moving from pilots to scaled DAAP deployments. By year-end 2025, DAAP-to-subscription conversion reached about a 10% run rate, up from the 5% to 10% range, marking progress toward a more recurring revenue base.

Capital Allocation and Shareholder Returns

The board authorized a $10 million share repurchase program funded from existing cash, signaling confidence in the company’s valuation. Management plans to balance buybacks with further debt reduction, but stressed that accelerating deleveraging remains the top capital allocation priority.

Softness in Contracted Revenue Trends

Year-to-date contracted revenue is running below last year as customers shift away from managed services and take a more cautious stance. After stripping out managed services, management estimates contracted revenue is roughly 15% to 20% behind where it would typically be at this point in the cycle.

Managed Services Contribution Not Expected to Repeat

Managed services contributed about $9 million of revenue in the first half of 2025, providing a notable boost to results. However, executives do not expect this contribution to recur in 2026 and are modeling very little managed services revenue in their outlook.

Conservative 2026 Revenue Outlook

For 2026, Optimizerx guided to revenue of $109 million to $114 million, essentially flat to slightly higher than 2025’s $109.4 million. This restrained top-line view reflects client conservatism and shifting business mix, even as the company still targets healthy adjusted EBITDA of $21 million to $25 million.

Gross Margin Normalization Ahead

Management cautioned that the standout Q4 gross margin of 74.8% was unusually high and driven by mix. For 2026, they expect gross margins to normalize to the mid-60% range as specialty messaging and channel mix tailwinds moderate across the full year.

Pressure on Revenue per Top Pharma Clients

Average revenue per top-20 pharmaceutical manufacturer slipped to $2.8 million from $3.0 million in 2024, a decline of about 7%. Management linked the drop to lower buy-ups and less data-related revenue, underscoring the impact of more conservative client spending patterns.

Shorter Contracts and Reduced Visibility

Customers are increasingly signing shorter contract durations, opting for quarter- to half-year pulses rather than longer terms. This shift is limiting near-term revenue visibility and contributing to a temporary pause in spending that management believes will normalize over time.

Guidance and Outlook Emphasize Profits Over Growth

Looking to 2026, the company expects revenue between $109 million and $114 million and adjusted EBITDA of $21 million to $25 million, reflecting a focus on profitability in a choppy demand environment. With nearly $19 million of free cash flow, improving leverage, and a new buyback authorization, management signaled they will prioritize debt reduction and disciplined, profitable growth.

Optimizerx’s earnings call painted a picture of a company leaning into profitability and cash discipline while navigating a softer, shifting revenue backdrop. For investors, the trade-off is slower top-line growth near term, but with strong margins, healthy cash generation, and rising recurring revenue penetration providing a solid foundation for future upside.